Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
| Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | ||
| Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
| Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
| Suboxone | Buprenorphine/naloxone | Opioid drug dependence (Substitution treatment) | List with clinical criteria and/or conditions | Complete | ||
| Intelence | Etravirine | HIV | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
| Stalevo | Carbidopa, levodopa and entacapone | Parkinsons Disease | List in a similar manner | Complete | ||
| Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | ||
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete |
Last Updated : May 20, 2024